SXTP60 DEGREES PHARMACEUTICALS,...

Nasdaq 60degreespharma.com


$ 0.09 $ -0.01 (-13.04 %)    

Wednesday, 07-Aug-2024 15:52:36 EDT
QQQ $ 434.88 $ -4.65 (-1.06 %)
DIA $ 387.79 $ -2.17 (-0.56 %)
SPY $ 518.50 $ -3.65 (-0.7 %)
TLT $ 95.87 $ -0.72 (-0.75 %)
GLD $ 220.55 $ -0.15 (-0.07 %)
$ 0.1035
$ 0.10
$ 0.10 x 2,000
-- x --
$ 0.09 - $ 0.10
$ 0.09 - $ 1.98
4,028,941
na
1.26M
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-20-2023 09-30-2023 10-Q
4 08-25-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 60-degrees-pharmaceuticals-announces-1-for-12-reverse-stock-split-effective-august-12-2024

Aims To Comply With Nasdaq $1.00 Minimum Bid Price Requirement; Trading To Continue Under Symbol "SXTP" With New CUSIP ...

 why-are-60-degrees-pharmaceuticals-shares-up-by-50-today

60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are surging on Friday following the company's announcement of clinica...

 60-degrees-pharmaceuticals-signs-clinical-trial-agreements-with-three-planned-trial-sites-for-tafenoquine-babesiosis-study

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tuft...

 reported-earlier-60-degrees-pharma-announces-irb-approval-of-clinical-study-of-tafenoquine-for-treatment-of-babesiosis-in-immunocompromised-patients-with-persistent-babesia-microti-despite-prior-treatment

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)))) ("60 Degrees Pharmaceuticals" or the "Company"), a pha...

 60-degrees-pharmaceuticals-enrolls-first-patient-in-clinical-trial-for-tafenoquine-to-treat-babesiosis-at-tufts-medical-center

The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-co...

 60-degrees-pharmaceuticals-announces-fda-orphan-drug-designation-for-tafenoquine-to-treat-acute-babesiosis

With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incenti...

 hc-wainwright--co-reiterates-neutral-on-60-degrees

HC Wainwright & Co. analyst Edward White reiterates 60 Degrees (NASDAQ:SXTP) with a Neutral.

 60-degrees-pharmaceuticals-begins-enrolling-for-a-clinical-trial-of-tafenoquine-for-babesiosis-at-tufts-medical-center

60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate th...

 60-degrees-q1-eps-003-up-from-113-yoy-sales-8066k-up-from-5166k-yoy

60 Degrees (NASDAQ:SXTP) reported quarterly earnings of $0.03 per share. This is a 102.65 percent increase over losses of $(1.1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION